Helicobacter pylori is a Gram-negative bacterium
that is responsible for gastric and duodenal ulcers. H. pylori uses the unusual mqn pathway with aminofutalosine
(AFL) as an intermediate for menaquinone biosynthesis. Previous reports
indicate that hydrolysis of AFL by 5′-methylthioadenosine nucleosidase
(HpMTAN) is the direct path for producing downstream
metabolites in the mqn pathway. However, genomic
analysis indicates jhp0252 is a candidate for encoding
AFL deaminase (AFLDA), an activity for deaminating aminofutolasine.
The product, futalosine, is not a known substrate for bacterial MTANs.
Recombinant jhp0252 was expressed and characterized as an AFL deaminase
(HpAFLDA). Its catalytic specificity includes AFL,
5′-methylthioadenosine, 5′-deoxyadenosine, adenosine,
and S-adenosylhomocysteine. The k
cat/K
m value for AFL is 6.8
× 104 M–1 s–1,
26-fold greater than that for adenosine. 5′-Methylthiocoformycin
(MTCF) is a slow-onset inhibitor for HpAFLDA and
demonstrated inhibitory effects on H. pylori growth.
Supplementation with futalosine partially restored H. pylori growth under MTCF treatment, suggesting AFL deamination is significant
for cell growth. The crystal structures of apo-HpAFLDA and with MTCF at the catalytic sites show a catalytic site
Zn2+ or Fe2+ as the water-activating group.
With bound MTCF, the metal ion is 2.0 Å from the sp3 hydroxyl group of the transition state analogue. Metabolomics analysis
revealed that HpAFLDA has intracellular activity
and is inhibited by MTCF. The mqn pathway in H. pylori bifurcates at aminofutalosine with HpMTAN producing adenine and depurinated futalosine and HpAFLDA producing futalosine. Inhibition of cellular HpMTAN or HpAFLDA decreased the cellular content of
menaquinone-6, supporting roles for both enzymes in the pathway.